---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000053"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:07:15.509535+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LENZ submits NDA for LNZ100 (aceclidine) to FDA for presbyopia treatment

## Summary
- NDA supported by Phase 3 CLARITY study: met all primary and secondary near vision endpoints.
- LNZ100 is an aceclidine-based eye drop targeting presbyopia, affecting ~1.8B people globally.
- No serious treatment-related adverse events observed over 30,000 study days.
- FDA has 60-day filing review period to determine NDA completeness for acceptance.

## SEC filing metadata
- accession: 0001815776-24-000053
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000053/0001815776-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000053/lenz-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000053
- JSON: https://secwatch.observer/filing/0001815776-24-000053.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.